TSXV:IFX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CAD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	115	N/A	N/A	N/A	1
12/31/2024	106	N/A	N/A	N/A	1
6/30/2024	102	4	-1	8	N/A
3/31/2024	98	1	-11	0	N/A
12/31/2023	94	1	-8	5	N/A
9/30/2023	92	2	-6	7	N/A
6/30/2023	96	5	-1	12	N/A
3/31/2023	104	8	1	17	N/A
12/31/2022	112	9	3	17	N/A
9/30/2022	115	10	3	14	N/A
6/30/2022	118	10	3	12	N/A
3/31/2022	114	8	5	9	N/A
12/31/2021	107	8	6	8	N/A
9/30/2021	104	8	6	9	N/A
6/30/2021	97	7	7	9	N/A
3/31/2021	91	5	11	13	N/A
12/31/2020	87	6	10	12	N/A
9/30/2020	83	5	10	12	N/A
6/30/2020	80	4	5	10	N/A
3/31/2020	80	4	3	9	N/A
12/31/2019	81	2	4	10	N/A
9/30/2019	85	2	2	8	N/A
6/30/2019	87	2	4	7	N/A
3/31/2019	88	2	1	3	N/A
12/31/2018	86	4	-3	1	N/A
9/30/2018	85	4	0	2	N/A
6/30/2018	85	4	-1	2	N/A
3/31/2018	87	4	N/A	5	N/A
12/31/2017	88	4	N/A	3	N/A
9/30/2017	86	3	N/A	2	N/A
6/30/2017	82	3	N/A	4	N/A
3/31/2017	76	2	N/A	2	N/A
12/31/2016	74	0	N/A	4	N/A
9/30/2016	72	1	N/A	2	N/A
6/30/2016	72	1	N/A	2	N/A
3/31/2016	73	1	N/A	1	N/A
12/31/2015	69	1	N/A	0	N/A
9/30/2015	68	1	N/A	2	N/A
6/30/2015	66	0	N/A	-1	N/A
3/31/2015	62	0	N/A	0	N/A
12/31/2014	61	0	N/A	-1	N/A
9/30/2014	59	0	N/A	-1	N/A
6/30/2014	59	-1	N/A	0	N/A
3/31/2014	58	0	N/A	-1	N/A
12/31/2013	56	0	N/A	2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van IFX boven de spaarquote ( 2.2% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van IFX naar verwachting sneller zal groeien dan de markt Canadian

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van IFX naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van IFX ( 8.3% per jaar) zal naar verwachting sneller groeien dan de markt Canadian ( 7% per jaar).

Hoge groei-inkomsten: De omzet van IFX ( 8.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van IFX naar verwachting over 3 jaar hoog zal zijn

Imaflex Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Imaflex Inc. Provides Earnings Guidance for the Full Year 2022

Price target increased to CA$1.95

Price target increased to CA$1.95

Imaflex Inc. Provides Earnings Guidance for the First Quarter 2022

Price target lowered to CA$0.90

Recent updates

Insider recently sold CA$59k worth of stock

Imaflex Inc. Announces CEO Changes, Effective October 28, 2024

Second quarter 2024 earnings released: EPS: CA$0.07 (vs CA$0.008 in 2Q 2023)

Imaflex (CVE:IFX) Is Reinvesting At Lower Rates Of Return

Market Might Still Lack Some Conviction On Imaflex Inc. (CVE:IFX) Even After 28% Share Price Boost

Investor sentiment improves as stock rises 24%

Revenues Not Telling The Story For Imaflex Inc. (CVE:IFX) After Shares Rise 48%

Investor sentiment improves as stock rises 18%

There May Be Some Bright Spots In Imaflex's (CVE:IFX) Earnings

First quarter 2024 earnings released: EPS: CA$0.04 (vs CA$0.018 in 1Q 2023)

Insufficient new directors

Full year 2023 earnings released: EPS: CA$0.01 (vs CA$0.18 in FY 2022)

Imaflex Inc., Annual General Meeting, Jun 13, 2024

Imaflex (CVE:IFX) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.06 in 3Q 2022)

Is Imaflex (CVE:IFX) A Risky Investment?

Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.066 in 2Q 2022)

Investor sentiment deteriorates as stock falls 18%

Insider recently sold CA$67k worth of stock

Imaflex Inc. Announces CEO Changes

Imaflex Inc. Appoints Roger Tambay as CEO

First quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.04 in 1Q 2022)

Imaflex Inc. Announces Chief Financial Officer Changes

Does Imaflex (CVE:IFX) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: CA$0.18 (vs CA$0.17 in FY 2021)

We Think Imaflex (CVE:IFX) Can Stay On Top Of Its Debt

Third quarter 2022 earnings released: EPS: CA$0.06 (vs CA$0.055 in 3Q 2021)

Imaflex Inc. Provides Earnings Guidance for the Full Year 2022

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Submits Advaseal® Registration Package to the EPA

Does Imaflex (CVE:IFX) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: CA$0.07 (vs CA$0.04 in 2Q 2021)

VP of Manufacturing recently sold CA$56k worth of stock

First quarter 2022 earnings released: EPS: CA$0.04 (vs CA$0.039 in 1Q 2021)

Is It Too Late To Consider Buying Imaflex Inc. (CVE:IFX)?

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Provides Earnings Guidance for the First Quarter 2022

Full year 2021 earnings released: EPS: CA$0.17 (vs CA$0.13 in FY 2020)

Imaflex Inc., Annual General Meeting, Jun 16, 2022

Imaflex Inc. Appoints Roberto Longo as Director, Chair the Audit Committee

Imaflex Inc. Announces Resignation of Mario Settino as Director

Vice-President of Corporate Affairs recently sold CA$56k worth of stock

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Imaflex (CVE:IFX) Could Easily Take On More Debt

Insider recently sold CA$520k worth of stock

VP of Manufacturing recently sold CA$98k worth of stock

Insider exercised options to buy CA$540k worth of stock.

Investors Should Be Encouraged By Imaflex's (CVE:IFX) Returns On Capital

Vice-President of Corporate Affairs exercised options to buy CA$735k worth of stock.

Second quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.007 in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imaflex Inc.'s (CVE:IFX) CEO For Now

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

First quarter 2021 earnings released: EPS CA$0.039 (vs CA$0.062 in 1Q 2020)

Here's Why I Think Imaflex (CVE:IFX) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS CA$0.13 (vs CA$0.031 in FY 2019)

Investor sentiment improved over the past week

Imaflex (CVE:IFX) Shareholders Will Want The ROCE Trajectory To Continue

Did Imaflex Inc. (CVE:IFX) Insiders Sell Shares?

Is Imaflex Inc.'s (CVE:IFX) Latest Stock Performance A Reflection Of Its Financial Health?

Imaflex Announces Positive Independent Results for the ADVASEAL Release Study

New 90-day high: CA$1.22

Is Imaflex (CVE:IFX) A Risky Investment?

What We Make Of Imaflex's (CVE:IFX) Returns On Capital

Imaflex (CVE:IFX) Is Growing Earnings But Are They A Good Guide?

Have Insiders Sold Imaflex Inc. (CVE:IFX) Shares Recently?

Insider recently sold CA$108k worth of stock

Revenue beats expectations

Imaflex Inc. Updates on Its ADVASEAL Study